Skip to main content

Table 5 HRs and 95% CIs showing the relationship between metabolic syndrome components and incidence of sudden cardiac death: Tehran Lipid and Glucose Study (1999–2018)

From: The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study

 

E/N

Model 1

Model 2

Model 3

Model 4

 

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

The JIS/IDF

 High WC

100/2219

1.62 (1.20–2.17)

 < 0.01

1.62 (1.21–2.18)

 < 0.01

–

–

1.46 (1.07–2.00)

0.02

 High FPG

88/1742

1.63 (1.22–2.18)

 < 0.01

1.66 (1.24–2.23)

 < 0.01

–

–

1.52 (1.12–2.05)

0.01

 High BP

114/2439

1.24 (0.91–1.70)

0.17

1.34 (0.98–1.84)

0.07

–

–

1.17 (0.84–1.61)

0.35

 High TG

111/2974

1.25 (0.93–1.70)

0.15

1.26 (0.93–1.71)

0.13

–

–

1.12 (0.81–1.56)

0.50

 Low HDL-C

114/3594

0.90 (0.67–1.22)

0.51

0.88 (0.65–1.20)

0.40

–

–

0.78 (0.57–1.08)

0.13

The ATP III

 High WC

70/2207

1.31 (0.92–1.86)

0.07

1.30 (0.91–1.86)

0.15

1.12 (0.78–1.61)

0.55

1.04 (0.72–1.53)

0.81

 High FPG

61/998

2.02 (1.49–2.76)

 < 0.01

2.06 (1.51–2.81)

 < 0.01

1.35 (0.92–1.99)

0.13

1.30 (0.87–1.94)

0.20

 High BP

112/2333

1.30 (0.96–1.77)

0.09

1.39 (1.02–1.91)

0.04

1.23 (0.89–1.69)

0.22

1.18 (0.85–1.63)

0.32

 High TG

109/2938

1.24 (0.92–1.67)

0.16

1.25 (0.92–1.68)

0.15

1.12 (0.83–1.52)

0.46

1.14 (0.82–1.58)

0.43

 Low HDL-C

113/3536

0.93 (0.69–1.26)

0.66

0.90 (0.67–1.22)

0.52

0.81 (0.60–1.10)

0.18

0.77 (0.56–1.06)

0.11

The WHO

 Dysglycemia

90/1691

1.91 (1.41–2.58)

 < 0.01

1.95 (1.44–2.65)

 < 0.01

1.49 (1.06–2.10)

0.02

1.31 (0.92–1.86)

0.14

 Obesity

147/3748

1.65 (1.06–2.54)

0.02

1.65 (1.07–2.54)

0.02

1.49 (0.96–2.30)

0.07

1.22 (0.77–1.91)

0.40

 High BP

93/1636

1.82 (1.33–2.49)

 < 0.01

1.96 (1.43–2.69)

 < 0.01

1.92 (1.40–2.64)

 < 0.01

1.79 (1.29–2.48)

 < 0.01

 Dyslipidemia

121/3223

1.45 (1.04–2.02)

0.03

1.43 (1.03–2.00)

0.03

1.34 (0.96–1.87)

0.08

1.15 (0.82–1.63)

0.42

  1. Model 1: Adjusted for age + sex
  2. Model 2: Model 1 + smoking + resting heart rate + family history of premature CVD
  3. Model 3: Model 2 + antihypertensive medications (only for ATP III definition) + lipid-lowering medications + glucose-lowering medications
  4. Model 4: Further adjustment with MetS components
  5. HR hazard ratio, CI confidence interval, MetS metabolic syndrome, JIS joint interim statement, IDF International Diabetes Federation, ATP III Adult Treatment Panel III, WHO World Health Organization, WC waist circumference, FPG fasting plasma glucose, BP blood pressure, TG triglycerides, HDL-C high-density lipoprotein cholesterol
  6. N: Subjects with each component for each definition of metabolic syndrome
  7. E: Number of SCD events
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840